Skip to main content

Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.

Glyconics Featured in Business Weekly



Glyconics, which is part of the Deepbridge Life Sciences EIS portfolio, has recently been featured in an article by Business Weekly regarding its pioneering scanning device, Glyconics-DS TM device. This device,which is similar in size to a mobile phone,offers an instant needle-free alternative to the traditional diabetes blood test. 

According to the results of two new studies published at the American Diabetes Association (ADA) annual meeting in San Diego, the pioneering scanning device can instantly reveal an individual’s risk of type 2 diabetes through a non-invasive fingernail reading. 

Dr Päivi Maria Paldánius, Chief Medical Officer of Glyconics, said: “Globally, there are 530 million people living with diabetes. That’s 1 in 10 adults. And yet, for every person with a diagnosis, there are up to three more people living with an undiagnosed condition. 

“The only way we can properly protect people from the disease, which can have devastating complications in later life, is by developing sustainable, affordable and pragmatic approaches to mass screening. Instant results enable people at risk to make essential lifestyle changes and be aware of their personal risk.” 

The two independent pilot studies – conducted in different countries (UK and Spain), contrasting healthcare settings and across diverse populations – demonstrated outstanding results, with the novel device proving greater than 95 per cent accuracy when identifying people at no immediate risk of diabetes. This means they were below the diagnostic marker for diabetes risk. 

Dr Kam Pooni, Chief Executive, Glyconics, added: 

“The team at Glyconics is incredibly excited about the potential impact this product will make in transforming diabetes screening and improving accessibility to vital healthcare information.” 

Click hereto find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).